Redeye updates on Xspray following a management call that provided some clarification on the Nilopki CRL. We view the CRL as a setback, but the read-across to Dasynoc should be limited: the CDMO remains inspection-ready and the outstanding item is the re-inspection itself, leaving a narrow but achievable window ahead of the 25 August PDUFA. That inspection outcome is the primary catalyst and will dictate share price direction from here.
LÄS MER
